Bicycle Therapeutics plc (BCYC)

Market Cap	337.38M -29.1%
Revenue (ttm)	72.59M +105.8%
Net Income	-218.96M
EPS	-3.16
Shares Out	69.71M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	401,858
Open	4.810
Previous Close	4.850
Day's Range	4.800 - 4.890
52-Week Range	4.240 - 9.550
Beta	1.65
Analysts	Buy
Price Target	13.90 (+187.19%)
Earnings Date	May 1, 2026

About BCYC

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company’s products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted imm...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 23, 2019
• Employees: 288
• Stock Exchange: NASDAQ
• Ticker Symbol: BCYC
• Website: https://www.bicycletherapeutics.com

Financial Performance

In 2025, Bicycle Therapeutics's revenue was $72.59 million, an increase of 105.77% compared to the previous year's $35.28 million. Losses were -$218.96 million, 29.5% more than in 2024.

Analyst Summary

According to 10 analysts, the average rating for BCYC stock is "Buy." The 12-month stock price target is $13.9, which is an increase of 187.19% from the latest price.

Price Target

$13.9

(187.19% upside)

Analyst Consensus: Buy